Organovo & Viscient Biosciences Collaborate for 3D Bioprinting in Liver Disease Research

Share this Article

Earlier this month, both Organovo and Viscient Biosciences announced their intent to collaborate on research for further studies into liver disease. There have been many interesting stories about Organovo and their advances—from promises regarding 3D printed kidney and liver tissue for pharmaceutical testing to new data about extended survival and function in animal test subjects.

This latest partnership of Organovo’s will of course continue to build on all the research they have in place, much of which is centered around bioprinting. Viscient’s interests lie in research surrounding drug discovery efforts for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.

“We continue to have excellent traction with a wide range of biopharmaceutical companies in evaluating our tissue systems to facilitate the discovery and development of novel drug candidates to treat liver disease. Our 3D disease models have the unique capability to demonstrate drug mechanisms of action and efficacy in a setting that closely mimics human livers,” said Taylor J. Crouch, CEO, Organovo.

“We’re proud to collaborate with Viscient’s talented team as they have a strong understanding of our expertise.  Our aim is to establish a custom platform that will support high-value drug profiling, and ultimately move our collaboration into a steady-state relationship.”

Such research is extremely important to the public, as around 100 million adults living in the US currently suffer from NAFLD, while an additional 20 million are living with NASH.

NAFLD is associated with inflammation, and an overload of fatty tissue in the liver. This important organ can be damaged, with lifelong consequences. As they collaborate, the hope is that Organovo and Viscient Biosciences will be able to create progressive and therapeutic treatments for NAFLD. Both conditions can lead to extremely serious illness, in the form of cirrhosis and cancer—and NASH is known as the second leading cause of liver transplants.

Organovo’s research is leading to many breakthroughs in studies regarding drug discovery, one of the greatest benefits of bioprinting. ExVive™ human liver and kidney tissues are used in the following:

  • Compound screening in disease models
  • Toxicology
  • Target and marker discovery/validation
  • Other types of drug testing

Non-alcoholic fatty liver disease

“Viscient is a strong believer in unlocking the power of 3D bioprinting to bring cures and treatments to patients with few options today,” said Keith Murphy, CEO, Viscient Biosciences. “In our pursuit of breakthrough therapies in important areas of medicine, we’re eager to tap into novel, complex and more accurate disease models. Organovo’s technology provides the potential for valuable and unprecedented insights as we target new drugs in areas of unmet medical need and strong commercial potential.

“Viscient’s plan goes arm and arm with Organovo,” Murphy said. “Viscient is going to be one of Organovo’s pharma customers.”

Headquartered in San Diego, Viscient is heavily involved in using 3D printing to make strides in drug development—and in fact, the company is comprised of former Organovo and Ardea Biosciences scientists and entrepreneurs. Find out more about them here.

Discuss this article and other 3D printing topics at 3DPrintBoard.com or share your thoughts below. 

[Sources / Images: XConomy: Globe NewsWire]

 

Share this Article


Recent News

Registration Rates Go Up This Week for Additive Manufacturing Strategies 2021

3D Systems’ New CEO Jeff Graves Discusses His Vision for 3D Printing



Categories

3D Design

3D Printed Art

3D Printed Food

3D Printed Guns


You May Also Like

AM-Flow Raises $4 Million to Automate Handling and Quality Control in 3D Printing

With 3D printing, any and all parts could be unique, which is a key advantage of the technology. It is also presents complex challenges when it comes to such crucial...

Wabtec Brings Railway 3D Printing to Pittsburgh’s Neighborhood 91 AM Campus

Wabtec Corporation (NYSE: WAB) has announced that it will be joining an additive manufacturing (AM) focused production site called Neighborhood 91, located at Pittsburgh’s International Airport Innovation Campus. Currently under construction,...

Featured

Deutsche Bahn Explains How Mobility Goes Additive is Driving Railway 3D Printing

Our industry pays very little attention to rail, an industry that has its very own certification requirements. What’s more, due to the nature of these large vehicles, rail parts are...

3D Printing News Briefs, October 10, 2020: Xometry, 3DEO, PostProcess Technologies, Digital Manufacturing Centre

We’re all business in today’s 3D Printing News Briefs. Xometry has made two new appointments to its board of directors, and 3DEO announced another shipment milestone. PostProcess Technologies has a...


Shop

View our broad assortment of in house and third party products.